Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography

Eur J Nucl Med. 1997 Jun;24(6):674-7. doi: 10.1007/BF00841408.

Abstract

This double-blind, placebo-controlled study assessed pharmacologically induced endogenous dopamine (DA) release in healthy male volunteers (n=12). Changes in endogenous DA release after injection of the psychostimulant drug methylphenidate were evaluated by single-photon emission tomography (SPET) and constant infusion of iodine-123 iodobenzamide ([123I]IBZM), a D2 receptor radioligand that is sensitive to endogenous DA release. Methylphenidate induced displacement of striatal [123I]IBZM binding, resulting in a significantly decrease in the specific to non-specific [123I]IBZM uptake ratio (average: 8.6%) in comparison with placebo (average: -1.9%). Moreover, injection of methylphenidate induced significant behavioural responses on the following items: excitement, anxiety, tension, and mannerisms and posturing. The results of this study demonstrate the feasibility of using constant infusion of [123I]IBZM and SPET imaging to measure endogenous DA release after methylphenidate challenge and to investigate neurochemical aspects of behaviour.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Behavior / drug effects
  • Benzamides*
  • Brain / diagnostic imaging*
  • Brain / metabolism
  • Central Nervous System Stimulants
  • Dopamine / metabolism*
  • Dopamine Antagonists*
  • Dopamine Uptake Inhibitors*
  • Double-Blind Method
  • Humans
  • Iodine Radioisotopes*
  • Male
  • Methylphenidate*
  • Pyrrolidines*
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Benzamides
  • Central Nervous System Stimulants
  • Dopamine Antagonists
  • Dopamine Uptake Inhibitors
  • Iodine Radioisotopes
  • Pyrrolidines
  • Methylphenidate
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
  • Dopamine